With more than 25 years of leadership experience in the CDMO and CRO sectors—including senior roles at Lonza, Catalent Pharma Solutions, and Ginkgo Bioworks—Dr. Mahdavi brings a proven track record of commercial innovation, global market development, and value-driven growth across the biopharmaceutical landscape. His appointment marks a pivotal moment for Biodextris as it advances its mission to become a world-class provider of end-to-end development and manufacturing services for biologics (mammalian and microbial), vaccines, and advanced therapeutic modalities.
"With our scientific heritage, top-tier talent, and a purpose-built, versatile GMP facility, Biodextris is uniquely positioned to help companies overcome the challenges of scaling complex biologics and emerging modalities," said Dr. Behzad Mahdavi. "My objective is to make Biodextris the partner of choice for innovative pharma and cell engineering companies—scaling early breakthroughs from bench to batch, quickly and reliably, with a flexible and approachable team that truly understands the science behind each product and embraces innovation."
Patrick Monpetit, who has served as Chairman of the Board, will transition to the role of Vice-Chairman and Lead Independent Director, and will continue to actively support the company.
"We are thrilled to welcome Dr. Mahdavi to Biodextris," said Cédric Héroux, CEO of Biodextris. "His global commercial acumen and strategic vision come at a pivotal time as we expand our state-of-the-art GMP facility. His leadership will be instrumental in strengthening our position as a trusted international partner in biologics development."
Meet Dr. Mahdavi and the Biodextris team at the upcoming BIO International Convention to learn more about the company's expanding capabilities and global vision.
About Biodextris:
Biodextris is a full-service Contract Development and Manufacturing Organization (CDMO) offering integrated biomanufacturing solutions to the biopharmaceutical industry. Built on the legacy of GSK's biologics and vaccine operations, Biodextris combines deep scientific expertise with advanced infrastructure to serve clients developing biologics, vaccines, and cell and gene therapies. The company delivers comprehensive services from early development to commercial manufacturing, with a strong emphasis on reliability, flexibility, and speed.
